G Szegedi

800 total citations
73 papers, 624 citations indexed

About

G Szegedi is a scholar working on Immunology, Rheumatology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, G Szegedi has authored 73 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 21 papers in Rheumatology and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in G Szegedi's work include Systemic Lupus Erythematosus Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Immune Cell Function and Interaction (9 papers). G Szegedi is often cited by papers focused on Systemic Lupus Erythematosus Research (18 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Immune Cell Function and Interaction (9 papers). G Szegedi collaborates with scholars based in Hungary, United States and France. G Szegedi's co-authors include Emese Kiss, Sándor Sipka, M Kávai, Margit Zeher, Pál Soltész, Katalin Pálóczi, S. Baráth, B. Fekete, Gabriella Lakos and Elena Czink and has published in prestigious journals such as The Lancet, Cellular and Molecular Life Sciences and British Journal of Haematology.

In The Last Decade

G Szegedi

65 papers receiving 572 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Szegedi Hungary 14 344 259 125 86 85 73 624
A. Léon France 14 354 1.0× 230 0.9× 49 0.4× 95 1.1× 70 0.8× 34 874
Anfisa Stanevsky Israel 10 272 0.8× 160 0.6× 130 1.0× 131 1.5× 122 1.4× 13 543
T R Dykman United States 9 422 1.2× 160 0.6× 164 1.3× 230 2.7× 113 1.3× 10 898
E. A. M. Van Der Voort Netherlands 12 275 0.8× 271 1.0× 114 0.9× 41 0.5× 38 0.4× 15 539
Fu-lin Tang China 15 385 1.1× 423 1.6× 89 0.7× 75 0.9× 59 0.7× 52 860
Joseph Golbus United States 11 404 1.2× 543 2.1× 110 0.9× 72 0.8× 139 1.6× 16 1.0k
Edward J. Fudman United States 9 131 0.4× 274 1.1× 95 0.8× 46 0.5× 104 1.2× 10 598
Dick L. Robbins United States 16 399 1.2× 264 1.0× 439 3.5× 102 1.2× 70 0.8× 50 807
Nina Daha Netherlands 13 249 0.7× 381 1.5× 113 0.9× 82 1.0× 69 0.8× 22 699
G T Swana United Kingdom 14 185 0.5× 478 1.8× 129 1.0× 60 0.7× 118 1.4× 17 888

Countries citing papers authored by G Szegedi

Since Specialization
Citations

This map shows the geographic impact of G Szegedi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Szegedi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Szegedi more than expected).

Fields of papers citing papers by G Szegedi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Szegedi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Szegedi. The network helps show where G Szegedi may publish in the future.

Co-authorship network of co-authors of G Szegedi

This figure shows the co-authorship network connecting the top 25 collaborators of G Szegedi. A scholar is included among the top collaborators of G Szegedi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Szegedi. G Szegedi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Májai, Gyöngyike, Emese Kiss, Tünde Tarr, et al.. (2013). Decreased apopto-phagocytic gene expression in the macrophages of systemic lupus erythematosus patients. Lupus. 23(2). 133–145. 37 indexed citations
2.
Sipka, Sándor, et al.. (2004). Decreased chemotaxis of human peripheral phagocytes exposed to a strong static magnetic field. Acta Physiologica Hungarica. 91(1). 59–65. 3 indexed citations
3.
Barta, Zsolt, István Csípő, Péter Antal‐Szalmás, et al.. (2001). [Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease].. PubMed. 142(42). 2303–7. 2 indexed citations
4.
Szekanecz, Zoltán, et al.. (1999). [Current aspects of the pathogenesis and clinical characteristics of otosclerosis: possibilities of drug therapy].. PubMed. 140(44). 2435–40. 10 indexed citations
5.
Csípő, István, M Kávai, Emese Kiss, et al.. (1997). Serum Complement Activation of SLE Patients During Plasmapheresis. Autoimmunity. 25(3). 139–146. 7 indexed citations
6.
Szűcs, Gabriella, M Kávai, Emese Kiss, István Csípő, & G Szegedi. (1995). Correlation of IgG Fc Receptors on Granulocytes with Serum Immune Complex Level in Systemic Lupus Erythematosus. Scandinavian Journal of Immunology. 42(5). 577–580. 14 indexed citations
7.
Gyimesi, Edit, M Kávai, István Csípő, & G Szegedi. (1992). A Sensitive Simple ELISA for Quantitation of Sensitizing IgG from Dissolved Erythrocytes. Scandinavian Journal of Immunology. 36(6). 875–878. 1 indexed citations
8.
Sipka, Sándor, et al.. (1991). Phagocytosis of autologous platelets by human neutrophil granulocytes.. PubMed. 39(2). 97–105. 1 indexed citations
9.
Sipka, Sándor, Katalin Dankó, Péter Nagy, et al.. (1991). Effects of suramin on phagocytes in vitro. Annals of Hematology. 63(1). 45–48. 5 indexed citations
10.
Zeher, Margit, et al.. (1990). CD5 positivity on peripheral blood B lymphocytes in patients with primary Sjögren's syndrome.. PubMed. 18(2). 75–8. 3 indexed citations
11.
Dénès, L, Gy. Hajós, L Szporny, et al.. (1987). The Effect of Thymopoietin 32–34 (TP3) on Suramin-Induced Inhibition on Delayed type Hypersensitivity in Guinea Pigs. Immunological Investigations. 16(4). 275–279. 3 indexed citations
12.
Czink, Elena, et al.. (1986). Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia.. PubMed. 43(4). 389–95. 6 indexed citations
13.
Mátyus, László, et al.. (1984). Cellular DNA content of T helper, T suppressor and B lymphocytes in SLE.. PubMed. 58(1). 37–41. 5 indexed citations
14.
Fekete, B., A. K. Pal, Ágnes Jakab, et al.. (1983). Clinical Correlates of Circulating Immune Complex Levels in Advanced Lung Cancer. Oncology. 40(2). 106–110. 5 indexed citations
15.
Szegedi, G, et al.. (1983). Potentiation of the defective monocyte chemotaxis in Hodgkin's disease by in vitro tuftsin treatment. Cancer Immunology Immunotherapy. 15(2). 162–3. 11 indexed citations
16.
Füst, George, B. Fekete, Ágnes Jakab, et al.. (1981). Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer. Journal of Immunological Methods. 46(3). 259–276. 10 indexed citations
17.
Kávai, M, et al.. (1980). Immunological Investigations in Acute and Chronic Human Pancreatitis. Digestion. 20(2). 100–105. 20 indexed citations
18.
Szegedi, G, et al.. (1979). Histamine-binding receptors and Fc receptors of T lymphocytes in SLE.. PubMed. 19. 137–41.
19.
Leövey, A, B. Fekete, & G Szegedi. (1975). Detection in serum of antilymphocyte-globulin administered in form of eye-drops.. PubMed. 9(1-2). 39–41. 1 indexed citations
20.
Gergely, P, G Szegedi, Gábor Szabó, B. Fekete, & G Petrányi. (1973). ROSETTE STIMULATION BY PLANT MITOGENS. The Lancet. 302(7834). 914–914. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026